A Phase 1 Dose-Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of XL844 Administered Orally to Subjects With Chronic Lymphocytic Leukemia
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
United States: Food and Drug Administration
XL844-001
NCT00234481
Name | Location |
---|---|
City of Hope National Cancer Center | Duarte, California 91010 |
UT MD Anderson Cancer Center | Houston, Texas 77030 |
UCSD Moores Cancer Center | La Jolla, California 93093 |